Cargando…

Whether Patients With Stage Ⅱ/Ⅲ Colorectal Cancer Benefit From Adjuvant Chemotherapy: A Modeling Analysis of Literature Aggregate Data

Objective: This study used model analysis to clarify the benefits and risks of postoperative adjuvant chemotherapy compared with surgery alone in patients with stage II/III colorectal cancer. Methods: Clinical trials involving patients with stage II/III colorectal cancer who underwent surgery alone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zha, Sijie, Li, Ting, Zheng, Qingshan, Li, Lujin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864068/ https://www.ncbi.nlm.nih.gov/pubmed/35222041 http://dx.doi.org/10.3389/fphar.2022.826785

Ejemplares similares

Testing whether the progression of Alzheimer’s disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data
por: Zhang, Ningyuan, et al.
Publicado: (2020)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma
por: Zhao, Zhuang, et al.
Publicado: (2020)

Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer
por: Gao, Lili, et al.
Publicado: (2021)

A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer
por: Cao, Bangrong, et al.
Publicado: (2017)

Feasibility Study of a Modified XELOX Adjuvant Chemotherapy for High-Recurrence Risk Patients With Operated Stage III Colon Cancer
por: Peng, Jianhong, et al.
Publicado: (2020)

Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer
por: Yuan, Zhen, et al.
Publicado: (2022)

Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer
por: Chen, Yuanyuan, et al.
Publicado: (2022)

Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis
por: Huang, Wen-Kuan, et al.
Publicado: (2021)

DKK1 as a robust predictor for adjuvant platinum chemotherapy benefit in resectable pStage II-III gastric cancer
por: Fan, Zhiyuan, et al.
Publicado: (2022)

Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy
por: Allen, Wendy L., et al.
Publicado: (2018)

Pathologic Factors Associated with Prognosis after Adjuvant Chemotherapy in Stage II/III Microsatellite-Unstable Colorectal Cancers
por: Kim, Jung Ho, et al.
Publicado: (2015)

Nutritional status predicts adjuvant chemotherapy outcomes for stage III colorectal cancer
por: Ihara, Keisuke, et al.
Publicado: (2019)

Elderly patients with stage II gastric cancer do not benefit from adjuvant chemotherapy
por: Guo, Jianping, et al.
Publicado: (2023)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study
por: Gao, Xianchun, et al.
Publicado: (2023)

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy
por: Min, Byung-Hoon, et al.
Publicado: (2011)

Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2017)

The efficacy of oxaliplatin combination adjuvant chemotherapy for elderly patients with stage III colorectal cancer
por: Hayashi, Naomi, et al.
Publicado: (2020)

Association between diabetes and adjuvant chemotherapy implementation in patients with stage III colorectal cancer
por: Kanehara, Rieko, et al.
Publicado: (2022)

Immunological nomograms predicting prognosis and guiding adjuvant chemotherapy in stage II colorectal cancer
por: Feng, Yang, et al.
Publicado: (2019)

Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2019)

EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function
por: Huang, Ching-Wen, et al.
Publicado: (2017)

GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy
por: Lin, Wey-Ran, et al.
Publicado: (2016)

Identification of a ferroptosis-related gene signature predicting recurrence in stage II/III colorectal cancer based on machine learning algorithms
por: Wang, Ze, et al.
Publicado: (2023)

An immune, stroma, and epithelial–mesenchymal transition‐related signature for predicting recurrence and chemotherapy benefit in stage II–III colorectal cancer
por: Cai, Du, et al.
Publicado: (2023)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study
por: Li, Pei-Jing, et al.
Publicado: (2021)

Adjuvant chemotherapy does not provide survival benefits to elderly patients with stage II colon cancer
por: Lee, Kil-yong, et al.
Publicado: (2019)

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.
por: Saarto, T., et al.
Publicado: (1997)

Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
por: Batra, Atul, et al.
Publicado: (2020)

A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy
por: De Mattia, Elena, et al.
Publicado: (2018)

Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa
por: Tan, Sarah Xinhui, et al.
Publicado: (2023)

Adjuvant Chemotherapy for Stage II Colon Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2020)

Effect of Adjuvant Chemotherapy on Elderly Stage II High-Risk Colorectal Cancer Patients
por: Lee, Yujin, et al.
Publicado: (2021)

Multi-center evaluation of machine learning-based radiomic model in predicting disease free survival and adjuvant chemotherapy benefit in stage II colorectal cancer patients
por: Zhu, Hui, et al.
Publicado: (2023)

Application of Prognostic Models Based on Psoas Muscle Index, Stage, Pathological Grade, and Preoperative Carcinoembryonic Antigen Level in Stage II-III Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy
por: Shan, Li, et al.
Publicado: (2022)

Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer
por: Ma, Gui-Fen, et al.
Publicado: (2019)

Clinical predictive value of in vitro anticancer drug sensitivity test for the therapeutic effect of adjuvant chemotherapy in patients with stage II–III colorectal cancer
por: MEKATA, EIJI, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_oupccdpeco8qbn434e8ngr1jjd